Aerovate Therapeutics Inc (AVTE)

$1.84

+0.06

(+3.37%)

Market is closed - opens 7 PM, 23 Jul 2024

Performance

  • $1.74
    $1.84
    $1.84
    downward going graph

    5.71%

    Downside

    Day's Volatility :5.71%

    Upside

    0.0%

    downward going graph
  • $1.25
    $32.42
    $1.84
    downward going graph

    32.07%

    Downside

    52 Weeks Volatility :96.14%

    Upside

    94.32%

    downward going graph

Returns

PeriodAerovate Therapeutics IncSector (Health Care)Index (Russel 2000)
3 Months
-92.08%
5.3%
0.0%
6 Months
-90.92%
6.3%
0.0%
1 Year
-89.17%
9.2%
0.0%
3 Years
-87.07%
13.1%
-19.9%

Highlights

Market Capitalization
51.3M
Book Value
$3.26
Earnings Per Share (EPS)
-3.03
Wall Street Target Price
2.25
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-47.79%
Return On Equity TTM
-80.58%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-88.3M
Diluted Eps TTM
-3.03
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.96
EPS Estimate Next Year
-1.51
EPS Estimate Current Quarter
-0.76
EPS Estimate Next Quarter
-0.75

Analyst Recommendation

Buy
    92%Buy
    7%Hold
    0
    0%Sell
Based on 13 Wall street analysts offering stock ratings for Aerovate Therapeutics Inc(by analysts ranked 0 to 5 stars)
Based on 13 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 22.28%

Current $1.84
Target $2.25

Technicals Summary

Sell

Neutral

Buy

Aerovate Therapeutics Inc is currently in a neutral trading position according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Aerovate Therapeutics Inc
Aerovate Therapeutics Inc
22.67%
-90.92%
-89.17%
-87.07%
-87.77%
Moderna, Inc.
Moderna, Inc.
-10.58%
20.19%
-0.41%
-64.88%
800.74%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.55%
12.06%
47.12%
82.44%
245.9%
Novo Nordisk A/s
Novo Nordisk A/s
-6.4%
26.39%
64.35%
193.51%
440.83%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.41%
12.78%
38.89%
147.34%
182.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Aerovate Therapeutics Inc
Aerovate Therapeutics Inc
0.88
NA
NA
-2.96
-0.81
-0.48
NA
3.26
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.45
31.45
1.46
44.4
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
45.05
45.05
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.94
31.94
0.53
17.05
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Aerovate Therapeutics Inc
Aerovate Therapeutics Inc
Buy
$51.3M
-87.77%
0.88
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$46.4B
800.74%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$117.2B
245.9%
31.45
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$591.7B
440.83%
45.05
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.9B
182.99%
31.94
39.46%

Insights on Aerovate Therapeutics Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 60.8% return, outperforming this stock by 150.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 193.5% return, outperforming this stock by 280.6%

Institutional Holdings

  • RA Capital Management, LLC

    28.69%
  • Sofinnova Ventures

    13.05%
  • TCG Crossover Management, LLC

    7.64%
  • Baker Bros Advisors LP

    5.83%
  • Cormorant Asset Management, LLC

    3.71%
  • Great Point Partners LLC

    3.08%

Company Information

aerovate is a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease. aerovate's initial focus is on advancing av-101, its dry powder inhaled formulation of the drug imatinib for the treatment of pulmonary arterial hypertension, or pah.

Organization
Aerovate Therapeutics Inc
Employees
51
CEO
Mr. Timothy P. Noyes M.B.A.
Industry
Healthcare

FAQs